Tests defibrotide to help prevent liver complications after stem cell transplant
Tests defibrotide before stem cell transplant in young people with sickle cell disease.
Key facts
- Who runs it
- New York Medical College
- Where
- Gainesville, Los Angeles, Milwaukee, and Valhalla, United StatesSee the 4 sites
- Trial code
- Registry title
- Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 1 Jul 2017
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Defibrotide
- Record updated
- 27 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children, adolescents and young adults with sickle cell disease or beta thalassemia who have had serious complications. They would have a stem cell transplant with defibrotide given to prevent liver vessel blockage.
- Age
- From 6 Months to 21 Years.
- Sex
- All sexes can join.
- Disease stage
- Sickle cell disease (homozygous Hemoglobin S, Hemoglobin S B0/+ thalassemia, or Hemoglobin SC) or beta thalassemia intermedia/majora, with at least one complication such as stroke, acute chest syndrome, repeated painful events, abnormal TCD study, silent infarct on head MRI, kidney damage from sickle cell, or avascular necrosis of the hip.
- Earlier treatment
- Some complications count only if hydroxyurea did not work, was refused or not followed, or before regular red blood cell transfusions. People who already had a stem cell transplant cannot join.
Main reasons for not taking part
- Taking blood thinners or clot-dissolving medicines
- Known allergic reaction to defibrotide
- Pregnant or breast-feeding
- Uncontrolled infection at study entry
- Has an unaffected HLA matched sibling donor willing to donate
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Disease: Homozygous Hemoglobin S Disease, or Hemoglobin S B0/+ thalassemia, or Hemoglobin SC Disease, or Beta thalassemia intermedia/majora
- Patients must demonstrate one or more of the following Sickle Cell Disease Complications
- Clinically significant neurologic event (stroke) or any neurologic deficit lasting >24 hours that is accompanied by an infarct on cerebral MRI
- Acute chest syndrome in the preceding two year period prior to enrollment that have failed, been non-compliant or declined hydroxyurea treatment, or prior to chronic RBC transfusion therapy, exchange transfusion or erythrocyte pheresis
- Recurrent painful events (at least 3 in the 2 years prior to enrollment or prior to chronic RBC transfusion therapy, exchange transfusion or erythrocyte pheresis)
- Abnormal TCD study requiring starting on chronic transfusion therapy and/or exchange transfusions
- At least one silent infarct lesion on a MRI scan of the head. Or (directly or probably related to SCD)
- Sickle Cell nephropathy
- Splenic sequestration requiring RBC transfusion
- Aplastic crisis requiring RBC transfusion
- Avascular necrosis of the hip diagnosed by MRI
- Two episodes or more of leg ulcerations
- Recurrent priapism
- Infant dactylitis
- all patients must meet disease, age, organ function and donor criteria
Who cannot take part
- Patients who are receiving concomitant systemic anticoagulants and/or fibrinolytic therapies
- Patients with a previously known hypersensitivity reaction to defibrotide
- Karnofsky or Lansky (age appropriate) Performance Score <50% (hemiplegia alone secondary to a previous stroke is not an exclusion)
- Patients who have previously received a HSCT will not be eligible
- Patients with documented uncontrolled infection at the time of study entry are not eligible
- Females who are pregnant or breast-feeding are not eligible
- Patients who have an unaffected HLA matched sibling donor willing to proceed to donation will not be eligible for this study
- Demonstrated lack of compliance with medical care
- Patients with clinically significant fibrosis or cirrhosis of the liver will not be eligible
- Patients with contraindications to the use of defibrotide
Where in United States
- University of FloridaGainesville, United StatesContact: Jordan Milner, MDTaking people
- University of California, Los AngelesLos Angeles, United StatesContact: Theodore B Moore, MDTaking people
- Medical College of WisconsinMilwaukee, United StatesContact: Julie A Talano, MDTaking people
- New York Medical CollegeValhalla, United StatesContact: Megan Campbell, RN, PNPTaking people
About the trial
What the trial wants to find out
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD.
The group in the trial
- Defibrotide prophylaxisTreatment being tested
defibrotide will be given prior to and during myeloablative immunotherapy conditioning (MAIC) followed by familial haploidentical (FHI) or matched unrelated donor (MUD) allogeneic stem cell transplantation (AlloSCT) with CD34 enrichment and t-cell addback in patients with high-risk sickle cell disease or beta thalassemia to reduced the risk and rate of the development of sinusoidal obstructive syndrome (SOS).
Treatment: Defibrotide
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Safety and Efficacy of Prophylactic Defibrotide Administration in Children, Adolescents, and Young Adults With Sickle Cell Disease or Beta Thalassemia Following Myeloablative Conditioning (MAC) and Haploidentical or Matched Unrelated Donor (MUD) Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback
- Plain-language title
- Tests defibrotide to help prevent liver complications after stem cell transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Donor chimerism and immune reconstitution following haploidentical transplantation in sickle cell disease.Frontiers in immunology, 2022
- Record updated
- 27 July 2026